We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+9.35%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$846M
AUM Growth
+$95.3M
Cap. Flow
+$37.1M
Cap. Flow %
4.39%
Top 10 Hldgs %
28.99%
Holding
143
New
11
Increased
56
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
EW icon
Edwards Lifesciences
EW
+$7.11M
2
IART icon
Integra LifeSciences
IART
+$6.94M
3
CI icon
Cigna
CI
+$6.83M
4
ALKS icon
Alkermes
ALKS
+$5.7M
5
IQV icon
IQVIA
IQV
+$5.62M

Top Sells

Rank Stock Value
1
AKRX
Akorn Inc
AKRX
+$11.9M
2
CNC icon
Centene
CNC
+$9.33M
3
INCY icon
Incyte
INCY
+$8.09M
4
LGND icon
Ligand Pharmaceuticals
LGND
+$6.18M
5
ALR
Alere Inc
ALR
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 92.73%
2 Financials 0.93%
3 Industrials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGIO icon
76
Agios Pharmaceuticals
AGIO
$2.36B
$2.31M 0.27%
45,000
– –
PRTA icon
77
Prothena Corp
PRTA
$453M
$2.22M 0.26%
41,000
– –
IBB icon
78
iShares Biotechnology ETF
IBB
$9.23B
$2.17M 0.26%
21,000
-15,000
-42% -$1.48M
NBIX icon
79
Neurocrine Biosciences
NBIX
$17.2B
$2.16M 0.26%
47,000
-21,000
-31% -$1.02M
PTLA
80
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$2.02M 0.24%
36,000
– –
SGEN
81
DELISTED
Seagen Inc. Common Stock
SGEN
$2.02M 0.24%
39,000
– –
HCA icon
82
HCA Healthcare
HCA
$82.3B
$1.86M 0.22%
21,300
– –
MRK icon
83
Merck
MRK
$315B
$1.76M 0.21%
28,820
– –
KITE
84
DELISTED
Kite Pharma, Inc.
KITE
$1.76M 0.21%
17,000
+3,000
+21% +$245K
CLVS
85
DELISTED
Clovis Oncology, Inc.
CLVS
$1.73M 0.2%
18,500
– –
HCSG icon
86
Healthcare Services Group
HCSG
$1.74B
$1.71M 0.2%
36,500
+20,000
+121% +$924K
RDUS
87
DELISTED
Radius Health, Inc.
RDUS
$1.65M 0.2%
36,500
– –
ANGO icon
88
AngioDynamics
ANGO
$558M
$1.65M 0.2%
101,700
– –
RARE icon
89
Ultragenyx Pharmaceutical
RARE
$2.88B
$1.61M 0.19%
42,000
– –
CAH icon
90
Cardinal Health
CAH
$53.5B
$1.56M 0.18%
20,000
– –
CYTO
91
DELISTED
Altamira Therapeutics Ltd
CYTO
$1.55M 0.18%
27
– –
MASI
92
DELISTED
Masimo
MASI
$1.55M 0.18%
17,000
-6,000
-26% -$551K
TFX icon
93
Teleflex
TFX
$5.96B
$1.45M 0.17%
7,000
+500
+8% +$100K
BIVV
94
DELISTED
Bioverativ Inc. Common Stock
BIVV
$1.37M 0.16%
22,750
– –
GMED icon
95
Globus Medical
GMED
$10.5B
$1.33M 0.16%
40,000
– –
ENDP
96
DELISTED
Endo International plc
ENDP
$1.28M 0.15%
115,000
– –
JUNO
97
DELISTED
Juno Therapeutics, Inc.
JUNO
$1.28M 0.15%
43,000
+6,000
+16% +$148K
EXEL icon
98
Exelixis
EXEL
$14.1B
$1.28M 0.15%
52,000
– –
MOH icon
99
Molina Healthcare
MOH
$11.7B
$1.14M 0.13%
16,500
– –
INO icon
100
Inovio Pharmaceuticals
INO
$92.1M
$1.13M 0.13%
12,000
– –
2 3
4
5 6

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q2 2017 Portfolio in Review

As of Q2 2017, Bellevue Group held 143 positions worth $846M, up 13% from $750M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Bellevue Group deployed $37.1M of net new capital in Q2 2017, opening 11 new positions and adding to 56 existing holdings. Its largest new stake was IQVIA: 66,520 shares worth $5.95M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Centene, an estimated $9.33M trimmed.

  • Bellevue Group's largest Q2 2017 buy was IQVIA: 66,520 shares worth $5.95M.
  • Bellevue Group added most to Edwards Lifesciences in Q2 2017, an estimated $7.11M increase.
  • Bellevue Group's biggest Q2 2017 reduction was Centene, cutting an estimated $9.33M.
  • Bellevue Group fully exited Akorn Inc in Q2 2017, selling an estimated $11.9M.
  • Bellevue Group's ten largest holdings make up 29% of its $846M portfolio in Q2 2017.
  • Bellevue Group opened 11 new positions and closed 11 in Q2 2017.
  • Bellevue Group's portfolio value rose 13% quarter-over-quarter to $846M.

Based on Bellevue Group's 13F filing for Q2 2017, filed 14 Aug 2017.